TY - JOUR
TI - Prasugrel in the treatment of acute coronary syndrome
AU - Spartalis, M.
AU - Tzatzaki, E.
AU - Spartalis, E.
AU - Paschou, S.A.
AU - Athanasiou, A.
AU - Iliopoulos, D.C.
AU - Siasos, G.
AU - Voudris, V.
JO - Future Cardiology
PY - 2020
VL - 16
TODO - 6
SP - 559-568
PB - Future Medicine Ltd
SN - 1479-6678, 1744-8298
TODO - 10.2217/fca-2020-0018
TODO - clopidogrel;  prasugrel;  ticagrelor;  antithrombocytic agent;  clopidogrel;  prasugrel;  purinergic P2Y receptor antagonist, acute coronary syndrome;  area under the curve;  Article;  atherosclerosis;  bleeding;  cardiovascular mortality;  cerebrovascular accident;  drug efficacy;  drug metabolism;  evidence based medicine;  heart infarction;  human;  incidence;  kidney failure;  liver failure;  maximum concentration;  nonhuman;  practice guideline;  priority journal;  risk factor;  thrombocyte aggregation;  percutaneous coronary intervention;  treatment outcome, Acute Coronary Syndrome;  Clopidogrel;  Humans;  Percutaneous Coronary Intervention;  Platelet Aggregation Inhibitors;  Prasugrel Hydrochloride;  Purinergic P2Y Receptor Antagonists;  Ticagrelor;  Treatment Outcome
TODO - Dual antiplatelet therapy is the mainstay therapy in patients with acute coronary syndrome. The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events. The newer P2Y12 inhibitors (prasugrel and ticagrelor) have better efficacy than clopidogrel. Prasugrel provides greater inhibition of platelet aggregation and has a rapid onset of action. Current acute coronary syndrome guidelines recommend the use of both newer P2Y12 inhibitors. However, emerging data have shown that prasugrel is more efficient than ticagrelor in reducing the incidence of nonfatal myocardial infarction, stroke or cardiovascular death, without increased risk of major bleeding. © 2020 Future Medicine Ltd.. All rights reserved.
ER -